Transition from a once-monthly formulation of a long-acting, injectable paliperidone palmitate to a once-every-3-month formulation treatment regimen in patients with schizophrenia demonstrated increased adherence to antipsychotic medication.
Transition from a once-monthly formulation of a long-acting, injectable paliperidone palmitate to a once-every-3-month formulation treatment regimen in patients with schizophrenia demonstrated increased adherence to antipsychotic medication.